Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus
Status:
Not yet recruiting
Trial end date:
2026-04-18
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the potential effectiveness of 24 weeks of
MMF within previously discovered immunologically defined subsets of SLE patients. Treatment
effects will be evaluated within the individual immunologically-homogenous subsets defined at
screening. This study will also explore and compare pre-randomization gene expression
patterns among responders and non-responders to MMF and MMF plus voclosporin, use
comprehensive immunophenotyping to study the immunologic changes that accompany treatment-
induced disease improvement and to better understand immunologic changes associated with the
loss of clinical response.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)